Gossamer Bio Enters Into Securities Purchase Agreement For Up to $250M Structured Private Placement
– $150 Million of Committed Capital: $25 Million Funded Upfront at Initial Closing, Plus an Additional $125 Million that Funds Upon FDA Acceptance of the Seralutinib NDA in PAH –– Potential for Up to an Additional $100
Gossamer Bio got a big promise of money ($250 million) to help pay for developing and selling a new medicine. This shows investors believe in the company's plan, which is a sign of confidence—but the money only fully arrives if the medicine gets approved.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.